Radiopharm Theranostics Limited · ASX:RAD
Radiopharm Theranostics — Investor Presentation (March 2022)
13 slides from Radiopharm Theranostics's investor presentation, Mar 28, 2022
Slide 1: CEO Presentation
For personal use only CEO PRESENTATION AUSTRALIA March 2022 Riccardo Canevari CEO, Radiopharm Theranostics Ltd
Slide 2: Disclaimer
DISCLAIMER The information in this presentation does not constitute personal Certain statements contained in this presentation, including, without For personal use only investment advice. The presentation is not intended to be comprehensive or limitation, statements containing the words “believes,”
Slide 3: Corporate Profile
CORPORATE PROFILE Market Information (as of March, 23, 2022) For personal use only ASX Code RAD IPO Date 25 Nov 2021 IPO Price $0.60 Trading Range since IPO (H/L) $0.495 – $0.245 Av. Daily Trading Vol 1.4 million No. of Shares on Issue 255.3 million Market Cap (As of March, 23, 2022) ~$64 million Ca
Slide 4: What Are Radiopharmaceuticals?
WHAT ARE RADIOPHARMACEUTICALS? For personal use only Diagnostic Therapeutic Radiopharmaceutical Radiopharmaceuticals Process involves attaching a radioactive isotope to a deliver radioactive isotopes to targeting agent such as a small molecule or antibody the tumour cells Diagnostics: low energy
Slide 5: Radiopharmaceuticals: Growth Opportunity
RADIOPHARMACEUTICALS: GROWTH OPPORTUNITY For personal use only Worldwide Oncology Market in 2025 = ~290B$ Radiopharmaceutical Therapies SOURCE 200 $190b OF BUSINESS 180 CAGR 9% as monotherapies or in I/O Therapies 160 combination 140 120 100 $85b 80 CAGR 22% 60 40 20 $14b CAGR 66% 0 Chemotherapy & I
Slide 6: Significant Progresses Since IPO
SIGNIFICANT PROGRESSES SINCE IPO For personal use only Completion of Phase 1 with nanobody in HER2+ breast cancer Letter of intent to start phase 1 in Australia in patients with PDL-1 Non-Small Cells Lung Cancer Nanomabs Manufacturing of GMP Nanobodies to support Phase I and Phase II (under fi
Slide 7: Radiopharm Theranostics at a Glance
RADIOPHARM THERANOSTICS AT A GLANCE *Deal signed with TerraPower Isotopes 4 unique assets 7 Isotope suppliers 8 clinical studies For personal use only secured by 1H2022 NEW Phase I by end 2022 8 to be started with Therapeutic NANOMABs AvB6 INTEGRIN Ac225* Re188 IMAGING PSA-mAb PIVALATE Lu177 Tb161 I
Slide 8: In a Fast Growing Market, RAD Has One of the Deepest Pipelines
IN A FAST GROWING MARKET RAD HAS ONE OF THE DEEPEST PIPELINES For personal use only Radiopharmaceutical Radiopharmaceutical Radiopharmaceutical Therapies represent the Therapies have untapped Therapies experiencing a new pillar in ~290B$ potential, in areas of high level of investor Oncology market
Slide 9: One of the Deepest Pipeline in the Sector
ONE OF THE DEEPEST PIPELINE IN THE SECTOR 1 trial readout + 4 new trial start 6 trial readout + 5 new trial start For personal use only 2022 2023 4 “First to market” or “Best in class” potential Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 8 IMAGING Phase 2a readout Phase 2a Phase 2a Phase 2a Phase 1 FPIA Brain Mets THE
Slide 10: Executive Leadership Team
EXECUTIVE LEADERSHIP TEAM For personal use only RICCARDO PROF DAVID DR THOM PAUL CANEVARI MOZLEY TULIP HOPPER MANAGING DIRECTOR / CEO CHIEF MEDICAL OFFICER CHIEF TECHNICAL OFFICER EXECUTIVE CHAIRMAN Riccardo was most recently Chief David was most recently at Cornell Thom has spent more than 25 Paul
Slide 11: Our Business Model
OUR BUSINESS MODEL VALUE CREATION INVESTMENTS For personal use only HIGH ZERO LOW Pipeline & Clinical Development structural costs personnel costs resource allocation 0 Rent or Owned Corporate Offices 6 Employees ONE of the deepest pipeline in the sector 0 Manufacturing facilities 6 Part-time consul
Slide 12: Contact Us
For personal use only CONTACT US Riccardo Canevari Paul Hopper CEO & MANAGING DIRECTOR Executive Chairman Radiopharm Theranostics Limited Radiopharm Theranostics Limited T +1 862 309 0293 T +61 406 671 515 E rc@radiopharmtheranostic.com E paulhopper@lifescienceportfolio.com W www.radiopharmtheranost
Slide 13: Despite Progresses, Unmet Needs in Cancer Remain High
DESPITE PROGRESSES, UNMET NEEDS IN CANCER REMAIN HIGH For personal use only SEER 13. Deaths come from U.S. Mortality RADIOPHARM THERANOSTICS LTD 2022 CONFIDENTIAL | 13
Radiopharm Theranostics — Investor Presentation (March 2022) on 6ix